Moderna (MRNA) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization of mNEXSPIKE, a new COVID vaccine, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 years and older. Following the CHMP’s positive opinion, the European Commission will make a marketing authorization decision.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- PayPal, SoundHound, Moderna, Devon, Bristol-Myers: Trending by Analysts
- Roblox downgraded, Lululemon upgraded: Wall Street’s top analyst calls
- Moderna price target lowered to $28 from $30 at Morgan Stanley
- Moderna’s Future: Balancing Growth Potential and Uncertainty with a Hold Rating
- Moderna initiated with a Hold at Jefferies